Teachers Retirement System of The State of Kentucky Purchases 2,070 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Teachers Retirement System of The State of Kentucky increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 5.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 42,628 shares of the biopharmaceutical company’s stock after buying an additional 2,070 shares during the period. Teachers Retirement System of The State of Kentucky owned 0.06% of Celldex Therapeutics worth $1,449,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its stake in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after acquiring an additional 1,167,659 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock worth $104,404,000 after purchasing an additional 100,000 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Celldex Therapeutics by 51.0% in the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after purchasing an additional 654,194 shares during the last quarter. Geode Capital Management LLC raised its stake in Celldex Therapeutics by 0.4% in the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock valued at $52,372,000 after purchasing an additional 6,557 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after purchasing an additional 479,068 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CLDX. Citigroup began coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Finally, Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Trading Down 0.6 %

CLDX opened at $26.04 on Wednesday. Celldex Therapeutics, Inc. has a 12 month low of $22.93 and a 12 month high of $53.18. The business’s 50-day moving average price is $27.10 and its 200-day moving average price is $33.53. The company has a market cap of $1.73 billion, a P/E ratio of -10.13 and a beta of 1.57.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 3.80% of the stock is owned by corporate insiders.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.